Brought to you by 
Medivation licenses exclusive rights to CureTech's Phase II cancer project pidilizumab
05 Oct 2021
Executive Summary
CureTech Ltd. granted Medivation Inc. exclusive global rights to develop and sell pidilizumab (CT011) in all indications, including cancer. The anti-PD-1 antibody is in Phase II studies for blood and solid tumors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medivation licenses exclusive rights to CureTech's Phase II cancer project pidilizumab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice